105
Participants
Start Date
January 15, 2018
Primary Completion Date
October 26, 2022
Study Completion Date
July 26, 2023
Zenocutuzumab
full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3
Trastuzumab
humanised IgG1 monoclonal antibody
Vinorelbine
antineoplastic drug of vinca alkaloid family
Endocrine therapy
same endocrine therapy is administered as the last line of endocrine therapy
Institut Jules Bordet, Brussels
UZ Leuven, Leuven
Grand Hôpital de Charleroi (GHdC), Charleroi
Institut Paoli Calmette, Marseille
Centre Georges-Francois Leclerc, Dijon
Hôpital Jean Minjoz, Besançon
Ramon Y Cajal Universitary Hospital, Madrid
Hospital Universitario 12de Octubre, Madrid
Centre Claudius Régaud, Toulouse
Sarah Cannon Research Institute, Nashville
Instituto Valenciano de Oncologia, Valencia
Centre Jean Perrin, Clermont-Ferrand
HCA Midwest Health, Kansas City
Centre Paul Strauss, Strasbourg
Centre Léon Bérard, Lyon
Cedars-Sinai Medical Center, Los Angeles
Centre René Huguenin, Saint-Cloud
Institute Gustave Roussy, Villejuif
Netherlands Cancer Institute NKI, Amsterdam
Champalimaud Clinical Centre, Lisbon
Hopistal San Antonio, Porto
Instituto Português Oncologia, Porto
Vall D'Hebron Institute of Oncology (VHIO), Barcelona
Hospital Clinic. C/Villaroel, Barcelona
Sarah Cannon Research Institute UK, London
Merus N.V.
INDUSTRY